Clinical Trial Update: A Study of Daclizumab (Zenapax) in Combination With Mycophenolate Mofetil (CellCept) and Sirolimus in Prevention of Acute Rejection in Heart Transplant Participants [Phase 4]

View source ↗

Summary

Phase 4 clinical trial assessing daclizumab with mycophenolate mofetil and sirolimus to prevent acute rejection in heart transplant recipients has been complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Transplantation

Drugs mentioned

• Daclizumab (daclizumab)
• MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL)
• Sirolimus (Sirolimus)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Heart Transplantation | Phase 4 | Status: COMPLETED